Protagenic Therapeutics, Inc. (KOL) PT00114 Webinar
July 13, 2021 10:00 am
Join in zoom app
Protagenic Therapeutics, Inc. is hosting a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.
The webinar will feature a presentation by KOL Dr. Maurizio Fava, Massachusetts General Hospital (MGH), who is serving as principal investigator in Protagenic’s upcoming Phase 1/2a clinical trial.
Protagenic’s management team will also provide an overview of the ongoing clinical development program and potential commercial opportunity for PT00114, which is known scientifically as teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulation of stress response in the brain.